JP2011144198A - Food having human serum hypocholesterolemic activity, and prophylactic or therapeutic agent for human serum hypercholesterolemia or human arteriosclerosis - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a food having human serum hypocholesterolemic activity and effective for improving lipid metabolism, and a prophylactic or therapeutic agent for human hypercholesterolemia or human arteriosclerosis. <P>SOLUTION: This food having human serum hypocholesterolemic activity contains one or two or more selected from the group consisting of broccoli, shepherd's-purse, radish, Turritis glabra, Ranunculus sceleratus, Isatis tinctoria, Cardamine regeliana, Barbarea orthoceras, Nasturtium officinale, Brassica juncea var. integlifolia, Brassica juncea, Wasabia japonica, Wasabia tenuis, Brassica rapa var. glabra, HINONA Brassica rapa, Brassica rapa var. neosuguki, Brassica rapa, Brassica rapa var. nippo-oleifera, cabbage, Brassica oleracrea, Raphanus sativus and radish greens. Also a prophylactic or therapeutic agent for human hypercholesterolemia or human arteriosclerosis containing these plants is disclosed. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  TECHNICAL FIELD The present invention relates to a food effective for improving lipid metabolism, having hepatocyte cholesterol synthesis inhibitory activity in humans and having a human serum cholesterol lowering effect, and a preventive or therapeutic agent for human hypercholesterolemia or human arteriosclerosis. It is.

  In recent years, an increasing number of middle-aged and elderly people and children suffering from lifestyle-related diseases such as myocardial infarction and arteriosclerosis. One of the major risk factors for myocardial infarction and arteriosclerosis is hypercholesterolemia.

  For the treatment of hypercholesterolemia, pharmaceuticals are generally administered and various dietary restrictions are added. However, the so-called HMG-CoA reductase inhibitor, which inhibits the action of enzymes in the cholesterol synthesis pathway in the body, which is the mainstream among pharmaceuticals, has side effects such as striated muscle melting and liver dysfunction and rebound. is there. In addition, a drug using an ion exchange resin that adsorbs a bile acid rich in cholesterol in the ileum and excretes it outside the body needs to be taken in a large amount, but it has a drawback of being uncomfortable and uncomfortable.

  Also, long-term dietary restrictions that are deprived of eating and forced to endure are not desirable.

  Therefore, it would be extremely ideal if serum cholesterol levels could be reduced in the normal diet without restricting diet and without administering drugs with side effects such as rhabdomyolysis and liver dysfunction. Is.

  In view of such circumstances, various studies have been conducted on functional foods effective in reducing human serum cholesterol and improving lipid metabolism.

  Therefore, the object of the present invention is to prevent human hypercholesterolemia or arteriosclerosis without side effects such as hepatic dysfunction and foods that have the above-mentioned drawbacks and have the effect of lowering human serum cholesterol levels. Alternatively, an object is to provide a therapeutic agent.

  The present inventor conducted a test by administering to a rat whether or not a mixture of various vegetable juices sold by the company (vegetable juice) has an effect of lowering serum cholesterol levels. Such an effect was not obtained. Therefore, it was thought that the said vegetable juice does not have a serum cholesterol level lowering effect.

  Later, in the company to which the present inventor belongs, there are many employees who have experienced a significant decrease in serum cholesterol levels during normal health examinations and later work-ups. The person who was born did not drink the above vegetable juice before the medical checkup, but had been drinking about 1 bottle of vegetable juice purchased by in-house sales between the medical checkup and the close examination. Surprisingly, it was found that the vegetable juice has an effect of lowering human serum cholesterol levels.

  Therefore, the present inventor has eagerly studied which component has the action with respect to the effect of the mixed vegetable juice on human serum cholesterol, and has further studied whether or not other edible plants have the action. As a result, broccoli, Nazuna, etc. have human hepatocyte cholesterol synthesis inhibitory activity, and in particular, the functional component in these water-soluble fractions has such activity, resulting in good serum cholesterol level reduction for humans It was found to have an action and a low density lipoprotein cholesterol (LDL-Chol) value lowering action. In addition, surprisingly, the combination of cabbage, mekibetsu, radish, and radish leaves with the above-mentioned other edible plants having human hepatocyte cholesterol synthesis inhibitory activity specifically enhances hepatocyte cholesterol synthesis inhibitory activity. The present inventors have found that human serum cholesterol level lowering action and human low density lipoprotein cholesterol (LDL-Chol) level lowering action are better. In addition, the above-mentioned plant-containing drug can be used as a prophylactic or therapeutic agent for human hypercholesterolemia without side effects such as liver dysfunction, or as a prophylactic or therapeutic agent for human arteriosclerosis. I found it. The present invention has been completed based on such a viewpoint.

That is, the present invention
Item 1: Broccoli, Nazuna, Suzushiro, Hatazao, Tagarashi, Taisei, Obata Netsubana, Yamagarashi, Takana, Karana, Wasabi, Yuri Wasabi, Hakusai, Hino A food having a human serum cholesterol lowering effect, comprising one or more selected from the group consisting of nakina, kakina, kabu, arabana, cabbage, mekibetsu, radish and radish leaves,
Item 2 (A) One or more species selected from the group consisting of cabbage, mecha beet, radish, radish leaves, and (B) broccoli, nazuna, suzushiro, hakatao, tadashi, taiji, obatabane One or more selected from the group consisting of Tsukubana, Yamagarashi, Ogarashi, Takana, Karashina, Wasabi, Yuri Wasabi, Hakusai, Hinona, Sukikina, Kabu and Abura. , A food having a human serum cholesterol lowering effect,
Item 3 (a) Broccoli, (b) At least one selected from the group consisting of cabbage and radish leaves, and (c) One or two selected from the group consisting of celery, lettuce, spinach, komatsuna, parsley and apple A food having a human serum cholesterol lowering action, comprising at least a species,
Item 4 Broccoli, Nazuna, Suzushiro, Hatazao, Tagarashi, Taisei, Obata Netsubana, Yamagarashi, Takana, Karana, Karashina, Wasabi, Yuri Wasabi, Hakusai, Hino A human hypercholesterolemia preventive or therapeutic agent comprising one or more selected from the group consisting of na, immediately, turnip, turnip, oil, cabbage, mekibetsu, radish and radish leaves,
Item 5: Broccoli, Nazuna, Suzushiro, Hatazao, Tagarashi, Taisei, Obata Netsubana, Yamagarashi, Takana, Karana, Wasabi, Yuri Wasabi, Hakusai, Hino The present invention relates to a prophylactic or therapeutic agent for human arteriosclerosis comprising one or more selected from the group consisting of nakina, kakina, kabu, arabana, cabbage, mekibetsu, radish and radish leaves.

  By ingesting the food of the present invention, it is possible to reduce human serum cholesterol levels without dietary restrictions or exercise guidance.

  Moreover, according to the human hypercholesterolemia preventive or therapeutic agent or human arteriosclerosis preventive or therapeutic agent of the present invention, there are no side effects such as striated muscle melting action and liver dysfunction.

Hereinafter, the present invention will be described in more detail.
I. Food of the present invention The food of the present invention is broccoli, nazuna, suzushiro, hazama, tadashi, taisai, daboshi nanabana, yamagarashi, kangarashi, takana, mustard, wasabi, It contains one or more selected from the group consisting of Yuri Wasabi, Hakusai, Hinona, Sakukina, Turnip, Abura, Kyabetsu, Mekibatsu, Daikon and Daikon Leaf.

  These edible plants exhibit hepatocyte cholesterol synthesis inhibitory activity, which is the mechanism of action that lowers serum cholesterol levels most efficiently in humans and lowers low-density lipoprotein cholesterol (LDL-Chol), which is said to be bad cholesterol. The food of the present invention contains these plants and thus has a good serum cholesterol level lowering action and LDL-Chol level lowering action on humans, and can be said to be an effective food for improving lipid metabolism. . Therefore, the food of the present invention can be ingested as health food, functional food, food for specified health use.

  In the present invention, among these edible plants, broccoli, nazuna, suzushiro, hazama, tadashi, taisai, dababa tsukana, yamagatari, kangarashi, takana, mustard, One type or two or more types selected from the group consisting of wasabi, lily wasabi, hakusai, hinano, immediately kin, turnip and oil are particularly preferred.

  These can be used in combination of two or more, in particular, one or more selected from the group consisting of cabbage, mekibetsu, radish, radish leaves, broccoli, nazuna, suzushiro, hazama, A group consisting of Takara, Taisei, Obata Tsubaki, Yamagarashi, Ogarashi, Takana, Karashina, Wasabi, Yuri Wasabi, Hakusai, Hinona, Immediately, Turnip and Abura It is preferable to use 1 type or 2 types or more selected in combination.

  Specific examples of preferred combinations include cabbage and broccoli, cabbage and radish leaves and broccoli, cabbage and broccoli and Chinese cabbage.

  In the food of the present invention, these plants may be used in a raw state, or those in which the raw state is heat-sterilized. In addition, the above raw state or heat-sterilized one is dried by hot air drying, freeze-drying treatment, etc., and used as a solid such as a film, plate or block or as a pulverized powder. Also good.

  Furthermore, it is also possible to use the raw state or the heat-sterilized one by crushing and squeezing it. Alternatively, it is also possible to use a liquid itself obtained by filtering the raw state or heat-sterilized product with a suitable filter cloth or the like, or a supernatant obtained by centrifuging the filtered liquid. The supernatant liquid may be dried by hot air drying or freeze-drying treatment or the like, and used as a film-like, plate-like or block-like solid or a powder obtained by pulverizing the solid.

  The total content of these plants in food varies depending on the food to be applied and individual differences (individual differences, race differences, etc.), and is not particularly limited as long as the effect of reducing human serum cholesterol is obtained. 0.01 to 100 w / w% is suitable, and preferably 1.0 to 99.9 w / w%.

  If the content in the food is less than 0.01 w / w%, a sufficient effect of improving lipid metabolism may not be expected.

  In addition to the above-mentioned plants, other ingredients can be added to the food of the present invention as long as the effect of lowering human serum cholesterol is not hindered.

  As other components, those known as plants having a cholesterol-lowering action such as kale, soybeans, oats, and barley can be added. Moreover, you may add what processed the other plants like a normal food, such as celery, lettuce, spinach, Japanese mustard spinach, parsley, apple, lemon, etc. similarly to the above.

  In particular, in the present invention, a food in which at least one selected from celery, lettuce, spinach, komatsuna, parsley, apple or lemon is added to a combination of broccoli and radish leaves is preferred.

  In the food of the present invention, as other ingredients, additives usually used in the field of food, for example, excipients such as starch, lactose, cellulose, dextrin, sugar alcohol, thickening polysaccharide; sucrose, maltose, Sweetening ingredients such as sorbitol, mannitol and oligosaccharides; nutritional supplements such as vitamins and calcium can also be added.

  The food of the present invention is a plant itself treated as described above at a suitable time in the process of producing food, a mixture diluted with excipients or a part of raw materials in food, ethanol or an aqueous solution thereof, etc. What was dissolved or dispersed in is added to the raw material, mixed according to a conventional method, and others can be produced by a usual production method for the food. Heat can also be applied during such mixing.

  Moreover, it can manufacture also by adding the plant itself processed as mentioned above, its mixture, and a solution to the once manufactured foodstuff, and mixing by a conventional method.

  The food of the present invention is limited to foods eaten by humans, and does not include feed (food) from animals other than humans (dogs, cats, rabbits, rats, mice, etc.).

  The food of the present invention is not particularly limited, and includes foods and drinks and luxury items. Specifically, fermentation products such as powder, tablets, capsules, candy, candy, nougat, chocolate, jelly, biscuits, cakes, bread, noodles, liquid beverages, vegetable juices, lactic acid beverages, miso, yogurt, kamaboko, chikuwa, etc. Aquatic products such as ham, sausage, processed milk and cheese, seasoning foods such as sauce, dressing, sauce and soy sauce, and health foods.

  The intake of the food of the present invention can be appropriately determined in the form of the food, the age, weight, sex, purpose, health status, etc. of the human being taken, and is not particularly limited. About 5 to 1,000 ml, if solid, about 0.1 to 100 g per day is preferably taken in several divided doses.

  The food of the present invention may be taken at any time of the day, before meals, after meals, and between meals, but is particularly effective when taken before breakfast, before lunch, before dinner, or on an empty stomach.

Furthermore, the food of the present invention can be used in combination with known hypercholesterolemia preventive or therapeutic agents such as mevalotin. When used in combination, the cholesterol-lowering action of the food of the present invention makes it possible to obtain a cholesterol-lowering action equivalent to the case of not reducing the use amount even if the use amount of the preventive or therapeutic agent is reduced, In the treatment, it is advantageous in terms of side effects.
II. The preventive or therapeutic agent of the present invention The edible plant contained in the food of the present invention such as broccoli, nazuna and the like has a human hepatocyte cholesterol synthesis inhibitory activity and has a human serum cholesterol lowering action. Therefore, the agent containing these plants can be used as an agent for preventing or treating human hypercholesterolemia, and further as an agent for preventing or treating human arteriosclerosis.

  Therefore, in the present invention, broccoli, nazuna, suzushiro, hazama, tadashi, taiji, daboshi natsubana, yagarashi, kangarashi, katakana, wasabi, yurisawabi , Human hypercholesterolemia or human arteriosclerosis prevention, or one or more selected from the group consisting of horny, hinona, immediately kina, turnip, oil, cabbage, cypress, radish and radish leaves A therapeutic agent is also included.

  The preferred types and combinations of these edible plants in the preventive or therapeutic agent of the present invention are the same as those in the food of the present invention.

  The preventive or therapeutic agent of the present invention includes excipients, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, dispersants, buffers, and preservatives that are commonly used in the preparation of pharmaceutical preparations. Additives such as additives, solubilizers, preservatives, flavoring / flavoring agents, stabilizers, and the like can be appropriately blended.

  The addition amount of these normal additives is not particularly limited as long as the desired effect is not hindered. For example, the additive amount is 0.001 to 90.0% by weight with respect to the total amount after addition, and preferably is 0.00. About 01 to 70.0% by weight can be added.

  The preventive or therapeutic agent for hypercholesterolemia of the present invention can be used in any form such as a liquid, tablet, granule, pill or the like according to the purpose, and treats plants such as broccoli in the same manner as the food of the present invention. , And can be prepared according to conventional methods for the dosage form.

  The present invention antiseptic or therapeutic agent is limited to those applied to humans, and does not include preventive or therapeutic agent for hypercholesterolemia or arteriosclerosis in animals other than humans (dogs, cats, rabbits, rats, mice, etc.) It is.

  The dose of the preventive or therapeutic agent of the present invention can be appropriately determined according to the form, age, weight, sex, purpose, etc. of the human to be administered, and is not particularly limited. About 5 to 1,000 ml per day, if it is a solid preparation, about 0.1 to 100 g per day is preferably taken in several divided doses. In addition, it may be taken at any time of the day, before meals, after meals, and between meals, but is preferably taken before breakfast, before lunch, before dinner, and on an empty stomach.

Hereinafter, the present invention will be described in more detail with reference to test examples. Unless otherwise specified, the following% display represents weight% (w / w%).
Test Example 1 Hepatocyte cholesterol synthesis inhibitory activity test Composition and preparation of test sample Vegetable juice of 1000 g of each plant mixture shown in Table 1 was filtered through a gauze filter cloth, and the obtained filtrate was centrifugally filtered at 10,000 G. The supernatant obtained by filtration was freeze-dried to obtain test samples shown in Table 2.

II. Test Method S-1 to S-8 shown in Table 2 were used as test substances, and tablets containing 5.6% pravastin sodium (trade name: mevalotin) were used as positive controls. These test substances were pulverized in a mortar and administered.

HepG2 cells (2 × 10 ⁵ cells) cultured in DMEM containing 10% FCS were implanted in a 6-well plate and cultured for 3 days (almost confluent). After removal of the medium, ¹⁴ C-acetic acid was added to the test substances S-1 to S-8 prepared in DMEM and the positive control and incubated for 2 hours. After removing the medium, washing with PBS, lysing the cells with KOH, and saponification Treatment was followed by extraction with ether and drying.

The extract obtained after drying was dissolved in acetone-ethanol, and the amount of radioactivity in the sediment after addition of 0.5% dichitonin was measured with a scintillation counter.
III. Test Results Table 3 shows the test results, that is, the concentrations of the test substance and the positive control substance that inhibit 50% of cholesterol synthesis in HepG2 cells.

  In Table 3, the positive control ratio of the titer is the 50% cholesterol synthesis inhibitory concentration of each test substance divided by 0.002% of the 50% cholesterol synthesis inhibitory concentration of the positive control (mevalotin). The titer of the test substance having the same weight as that of the positive control is expressed as a positive control ratio.

In addition, the titer corrected yield conversion (standard S-7) is to obtain the yield of the test sample from Table 2 and calculate S-
7 was corrected for the positive control ratio of the titer, and was shown so that the cholesterol synthesis inhibitory activity could be traced back to the original plant mixture and compared between the test samples.

  Therefore, theoretically, clinical trials of test sample S-7 and positive control (mevalotin) administration to the hypercholesterolemia group were conducted, and the results were compared. When the indicated dose can be found, the dose of each plant mixture can be calculated based on this titer correction value.

In Test Example 1, the cholesterol synthesis inhibitory activity was found only in the water-soluble fraction of each test sample, and the ethanol fraction, acetone fraction, and acetic acid of each test sample were simultaneously performed. No cholesterol synthesis inhibitory activity was found in the ethyl fraction.
Test Example 2 Human Clinical Test Among test samples in which cholesterol synthesis inhibitory activity in hepatocytes was found in Test Example 1, T-1, T-5, T-7, and S-7 were hypercholesterolemia groups A human clinical trial was conducted on the subjects, and the correlation between the presence or absence of clinical effect and the clinical effect and cholesterol synthesis inhibitory activity was evaluated.
I. Contents of clinical trials 1) Divide 80 patients with hypercholesterolemia into 4 groups and have 2 test drinks (canned drinks) shown in Table 4 taken for 4 weeks per day for improvement of blood indicators such as serum cholesterol level The effect was evaluated.
2) Blood was collected before and after the test period of 4 weeks (0 weeks and 4 weeks).
3) During the study period, except for the test sample drinking, the normal eating habits and daily life were performed, and no dietary restrictions or exercise instructions were given.
II. Subjects of clinical trials Hypercholesterolemia patients that meet the following criteria were used as controls.
1) Selection criteria
i) Those whose serum total cholesterol level is 240 (mg / dl) or more
ii) Those who understand the purpose and content of this study and have agreed to become subjects 2) Exclusion criteria
i) Those who have complications such as liver disease or diabetes
ii) Patients taking hypercholesterolemia and taking therapeutic drugs
iii) Other persons who are judged inappropriate by the doctor in charge
III. Test sample Each can of 160 g can be filled with the filtrate obtained by filtering vegetable juice obtained by squeezing the plant mixture T-1, T-5, T-7 shown in Table 1 Use as a test sample. 9.92 g of S-7 shown in Table 2 in an amount corresponding to 160 g of T-7 is dissolved in purified water, and 160 g is similarly filled into a can of 160 g to make a test sample.

IV. Test Results Table 5 shows the change and reduction rate of the total cholesterol level before and after the clinical test of the 4 groups tested, and Table 6 shows the change and reduction rate of the LDL cholesterol level.

  From Table 5, it can be seen that the total cholesterol level is reduced in any of the O-1 to O-4 groups by drinking the food of the present invention.

  In particular, in the O-4 group, the total cholesterol level has decreased by an average of 11.9% after 4 weeks of drinking. This decrease rate is almost comparable to the decrease rate of 11.1% when 5 mg per day is administered for 4 weeks, compared with the decrease rate of mevalotin administered as a positive control in Test Example 1. The prescribed dose of mevalotin is 10 mg per day, and in this case, the total cholesterol level is reduced by 18 to 20%.

  From the amount of change in cholesterol in Tables 5 and 6, it is clear that the main factor for the decrease in the total cholesterol level is the decrease in LDL cholesterol.

  When the titer correction shown in Table 3 is compared with the results in Table 5, when the titer of S-7 is 1, O-3 (T-7) is 11.5%, O-4 (S The decrease rate was almost the same as ▲ 11.9% of -7), which is almost the same as the one-to-one titer correction.

O-1 (T-1) is 10.6%, 0.89: 1 compared to -11.9% of O-4 (S-7), and the titer correction is 0.90: 1. That is almost consistent.
O-5 (T-5) is ▲ 3.5%, 0.29: 1 compared to ▲ 11.9% of O-4 (S-7), and is 0.34: 1 for titer correction. That is almost consistent.

In addition, the safety-related indicators, such as GOT, GPT, ALP, γ-GTP, and LDH-5, which are liver-related indicators, are not changed, and CPK, LDH-1, LDH- 2. No changes were observed in LDH-3, LDH-4, creatine, creatinine, etc., and no changes were observed in BUN, creatinine, uric acid, etc. of kidney-related indicators.

In addition, no changes were observed in serum total protein, albumin, immunoglobulin, cholinesterase, serum amylase, etc. in nutritional satisfaction-related indicators, and red blood cell count, hemoglobin content, platelet count, hematocrit, leukocyte count, leukocyte fraction (preferably Basophils, eosinophils,
There was no change in lymphocytes, monocytes, etc.).

  From the above, the human serum cholesterol lowering action of the food of the present invention is mainly due to the hepatocyte cholesterol synthesis inhibitory activity, and by selectively reducing the low density lipoprotein cholesterol (LDL-Chol) value, It is clear that it is effective in lowering cholesterol and improving lipid metabolism.

  The serum cholesterol lowering effect of the food of the present invention is weak compared to mevalotin, a pharmaceutical product, but no side effects on the liver or myocardium were observed.

Therefore, the food of the present invention is a mixture of common vegetables eaten in a normal diet without worrying about unknown side effects as found in new drugs, and can reduce human serum cholesterol. Thus, when a person with high cholesterol uses it prophylactically, it is considered to have sufficient health significance.
Comparative Test Example 1
The test results of administering mixed vegetable juice containing appropriate amounts of broccoli, cabbage, radish, celery, lettuce, spinach, Japanese mustard spinach, parsley and apple to rats are shown below.

  10 SD-SPF rats (male, 4 weeks old) were divided into 2 groups, group A (control group) was allowed to freely ingest only the standard diet, and group B (test group) was mixed with the standard diet. Vegetable juice was given freely.

  In general, when performing prevention or treatment for lowering cholesterol levels, a diet that is not excessive in fat, such as a fat-loaded diet, is not used even if dietary restriction is not performed. Therefore, in the test example of the present invention, in order to evaluate the serum cholesterol lowering effect of the mixed vegetable juice, a standard diet was consumed instead of a fat-loaded diet.

  Table 7 shows the total cholesterol levels of both groups before the start of the test and 4 weeks after the start of the test.

  In group B given mixed vegetable juice in addition to the standard diet, the total cholesterol level was reduced, but in group A fed the standard diet, the total cholesterol level was similarly reduced. Moreover, when the change amount and change rate of A group and B group were compared, the A group which gave only the standard diet was higher.

  The above results indicate that the mixed vegetable juice containing broccoli, cabbage, radish leaves, etc. does not have the effect of reducing the total cholesterol of the rat.

Claims (4)

A beverage for lowering LDL cholesterol for humans having higher cholesterol, comprising broccoli and cabbage, and having a human serum LDL cholesterol lowering action by broccoli and cabbage. Furthermore, the drink of Claim 1 containing the 1 type (s) or 2 or more types chosen from the group which consists of celery, lettuce, spinach, Japanese mustard spinach, parsley, an apple, lemon, and a radish leaf. The beverage according to claim 1 or 2, which is a food for specified health use. The beverage according to any one of claims 1 to 3, which is a vegetable juice.